RecruitingPhase 3NCT06679881

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

A Long-term, Open-label Study to Evaluate the Safety and Efficacy of Orally Administered Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema

Sponsor

Pharvaris Netherlands B.V.

Enrollment

170 participants

Start Date

Feb 1, 2025

Study Type

INTERVENTIONAL

Conditions

Hereditary Angioedema (HAE)

Summary

This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema

Eligibility

Min Age: 12 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Deucrictibant for people with hereditary angioedema (hae). The study is currently recruiting participants at 62 locations. People eligible for this study include aged 12 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDeucrictibant

Deucrictibant extended-release tablet for once daily oral use

Locations(62)

Study Site

Birmingham, Alabama, United States

Study Site

Scottsdale, Arizona, United States

Study Site

Little Rock, Arkansas, United States

Study Site

San Diego, California, United States

Study Site

Santa Monica, California, United States

Study Site

Walnut Creek, California, United States

Study Site

Wheaton, Maryland, United States

Study Site

St Louis, Missouri, United States

Study Site

Las Vegas, Nevada, United States

Study Site

Hershey, Pennsylvania, United States

Study Site

Dallas, Texas, United States

Study Site

Milwaukee, Wisconsin, United States

Study Site

Corrientes, Argentina

Study Site

Pilar, Argentina

Study Site

Salta, Argentina

Study Site

Melbourne, Australia

Study Site

Melbourne, Australia

Study Site

Perth, Australia

Study Site

Sydney, Australia

Study Site

Vienna, Austria

Study Site

Ribeirão Preto, Brazil

Study Site

Salvador, Brazil

Study Site

Santo André, Brazil

Study Site

São Paulo, Brazil

Study Site

São Paulo, Brazil

Study Site

Sofia, Bulgaria

Study Site

Edmonton, Canada

Study Site

Montreal, Canada

Study Site

Beijing, China

Study Site

Grenoble, France

Study Site

Berlin, Germany

Study Site

Frankfurt, Germany

Study Site

Munich, Germany

Study Site

Hong Kong, Hong Kong

Study Site

Budapest, Hungary

Study Site

Dublin, Ireland

Study Site

Padova, Italy

Study Site

Palermo, Italy

Study Site

Roma, Italy

Study Site

Hiroshima, Japan

Study Site

Kanagawa, Japan

Study Site

Osaka, Japan

Study Site

Tokyo, Japan

Study Site

Krakow, Poland

Study Site

Martin, Slovakia

Study Site

Cape Town, South Africa

Study Site

Daegu, South Korea

Study Site

Seoul, South Korea

Study Site

Barcelona, Spain

Study Site

Ankara, Turkey (Türkiye)

Study Site

Istanbul, Turkey (Türkiye)

Study Site

Izmir, Turkey (Türkiye)

Study Site

Birmingham, United Kingdom

Study Site

Birmingham, United Kingdom

Study Site

Brighton, United Kingdom

Study Site

Bristol, United Kingdom

Study Site

Cambridge, United Kingdom

Study Site

London, United Kingdom

Study Site

London, United Kingdom

Study Site

Oxford, United Kingdom

Study Site

Plymouth, United Kingdom

Study Site

Southampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06679881

Related Trials

A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple Countries

NCT0725193324 locations

Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)

NCT0742849948 locations

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT0729844710 locations

A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema

NCT072933641 location

A Study of Lanadelumab in Teenagers and Adults With Hereditary Angioedema (HAE) in the Kingdom of Saudi Arabia

NCT072636851 location